Hims & Hers Health Are Falling Today: What's Going On?
Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...
Seeking Alpha24d
Hims & Hers: Driving Growth In Wellness
Adding liraglutide in 2025 and scaling 503A facilities to boost personalized care and subscriber growth. Hims & Hers Health, Inc. (NYSE:HIMS) leads the fast-growing health and wellness market ...
Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Hosted on MSN7d
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust ...
Investing28d
BofA reiterates underperform rating on HIMS shares amid FDA leadership change
including the launch of liraglutide, the first generic GLP-1, in 2025. These are the recent developments. While BofA Securities maintains an Underperform rating on Hims and Hers (NYSE:HIMS ...
The weight-loss drug boom has become one of the internet's biggest scams
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
NBC New York15d
The weight-loss drug boom has become one of the internet's biggest scams
Besides that partner, BPI Labs, Hims & Hers acquired another, MetasourceRx, in September. The company also sells branded Ozempic and next year will offer liraglutide, the first generic GLP-1.